These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22612537)

  • 1. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease.
    Lawrance IC
    Expert Opin Investig Drugs; 2012 Jul; 21(7):975-84. PubMed ID: 22612537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update.
    Cesarini M; Fiorino G
    Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells.
    Picarella D; Hurlbut P; Rottman J; Shi X; Butcher E; Ringler DJ
    J Immunol; 1997 Mar; 158(5):2099-106. PubMed ID: 9036954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of 4C8 antigen, a novel transendothelial migration-associated molecule on activated T lymphocytes, in inflammatory bowel disease.
    Oshitani N; Hato F; Kitagawa S; Masuyama J; Higuchi K; Matsumoto T; Arakawa T
    J Pathol; 2002 Aug; 197(5):589-94. PubMed ID: 12210077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting T-cell migration in inflammatory bowel disease.
    Marsal J; Agace WW
    J Intern Med; 2012 Nov; 272(5):411-29. PubMed ID: 22946654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.
    Gerner RR; Moschen AR; Tilg H
    Dig Dis; 2013; 31(3-4):328-35. PubMed ID: 24246983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapies for inflammatory bowel disease: from the bench to the bedside.
    Danese S
    Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease.
    Ten Hove T; The Olle F; Berkhout M; Bruggeman JP; Vyth-Dreese FA; Slors JF; Van Deventer SJ; Te Velde AA
    J Leukoc Biol; 2004 Jun; 75(6):1010-5. PubMed ID: 15020649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune dysfunction in inflammatory bowel disease.
    Neuman MG
    Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
    Ghosh N; Chaki R; Mandal SC
    Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory peptides and proteins in inflammatory bowel disease.
    Veljaca M
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1387-94. PubMed ID: 11890353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical model of the roles of T cells in inflammatory bowel disease.
    Lo WC; Arsenescu RI; Friedman A
    Bull Math Biol; 2013 Sep; 75(9):1417-33. PubMed ID: 23760658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma.
    Dotan I; Allez M; Nakazawa A; Brimnes J; Schulder-Katz M; Mayer L
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1630-40. PubMed ID: 17347451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S; Becker E; Schulze LL; Neurath MF
    Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a regulatory "defect" for CD4 positive intestinal T cells in vitro in patients with IBD compared to normals.
    Niessner M; Gerok W; Volk BA
    Adv Exp Med Biol; 1995; 371B():1267-71. PubMed ID: 7502797
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.